| | | |

Dog Research May Lead to Over-the-Counter Mesothelioma Test

over-the-counter mesothelioma test

A cancer research project involving dogs could eventually pave the way for an over-the-counter mesothelioma test. 

Researchers in Florida recently published a study suggesting that dogs may be able to detect lung cancer with surprising accuracy.

If they can determine which cancer biomarkers the dogs detect, they may be able to develop an over-the-counter mesothelioma test. 

Can Dogs Smell Lung Cancer?

The new study comes from the Florida campus of the Lake Erie College of Osteopathic Medicine (LECOM). Researchers there are working with a canine training and research firm called BioScentDX.

According to LECOM, a dog’s sense of smell is at least 10,000 times stronger than a person’s. The research team chose Beagles for the tests because they are among the most sensitive to smell of all dog breeds. 

The goal of the current project was to see if Beagles could correctly identify blood serum samples from people with lung cancer. If scientists can figure out how they do it, it could be a breakthrough for cancer research. 

Lung-related cancers like pleural mesothelioma are notoriously difficult to detect in the early stages. An over-the-counter mesothelioma test could save lives by allowing treatment to start earlier when it is more likely to be effective. 

In Search of an Over-the-Counter Mesothelioma Test

For eight weeks, the researchers exposed three Beagles to wall-mounted canisters containing blood serum. Only one of the containers held serum from a lung cancer patient. Each time a dog sat in front of the right canister – and ignored the others – it received a treat.

The Beagles correctly identified the cancer samples 96.7 percent of the time. They correctly ignored non-cancerous samples 97.5 percent of the time.

Based on these results, LECOM and BioScentDX launched a second study. This one measures the dogs’ ability to detect several kinds of cancer from breath samples. Early results show this data could also contribute to the development of an over-the-counter mesothelioma test. 

“This canine scent detection research could potentially change the whole paradigm of future early cancer detection,” says Thomas Quinn, DO. Dr. Quinn is a clinical professor of family and occupational medicine at LECOM and lead investigator of the study. “The objective is to advance canine scent detection of cancer from the realm of research into the sphere of evidence-based, early cancer detection.”

Right now, pleural mesothelioma detection involves blood and lung fluid tests, as well as X-rays and CT scans. These tests may be invasive or expensive or both. Many are not accessible to mesothelioma patients in rural communities. 

If the dogs can help point the team to the right cancer biomarkers, the information could help scientists develop a simple, inexpensive, over-the-counter mesothelioma test.

Source:

“Beagles Detect Lung Cancer With 97 Percent Accuracy In New LECOM Research”, June 25, 2019, LECOM website, https://lecom.edu/beagles-detect-lung-cancer-with-97-percent-accuracy-in-new-lecom-research/

Similar Posts

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • |

    Mesothelioma Blood Test May Be Possible

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Micro-RNAs May Offer New Way to Fight Mesothelioma

    Scientists at one of the world’s top mesothelioma research centers, the Asbestos Diseases Research institute in Sydney, Australia, say that restoring the expression of certain micro RNAs in the cells of mesothelioma patients may offer a new way to fight the disease. A microRNA is a small RNA molecule which is involved in the regulation of gene expression. According to a new report in the Annals of Oncology, the Australian scientists found reduced expression of the micro RNA-15 family (miR-15/16) in the cells of mice with mesothelioma. “When malignant pleural mesothelioma cell lines were compared with the normal mesothelial cell line MeT-5A, the downregulation of miR-15/16 was 2- to 10-fold,” they report. This finding is consistent with previous cancer research…

  • | |

    Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma

    Mesothelioma researchers in China say a biopsy method that involves a single skin puncture can produce good diagnostic results for mesothelioma patients with little pain or risk. The study focused on percutaneous (through the skin) biopsy in patients who had unexplained fluid buildup or swelling in their abdomens. Abdominal distension and fluid buildup (called ascites) can be signs of peritoneal mesothelioma, a rare but aggressive cancer of the abdominal lining caused by exposure to asbestos. Peritoneal mesothelioma accounts for less than 30% of all mesothelioma cases. Because the symptoms may be vague and often develop many decades after asbestos exposure, peritoneal mesothelioma can be especially challenging to diagnose.  Misdiagnosis and under-diagnosis are not uncommon. In the newest study on percutaneous…

  • | |

    Treatment Uses Herpes Virus to Shrink Mesothelioma Tumors

    Researchers at a hospital in Sheffield, England are testing a potential new mesothelioma treatment based on the same virus that causes herpes. The small-scale trial is the first in the world to test the modified herpes simplex virus, HSV1716, in human mesothelioma patients. HSV1716 has been genetically engineered to infect and kill cancer cells without harming healthy cells. In laboratory studies on mesothelioma and some other cancers, it has been shown to be effective at shrinking tumors while causing limited toxicity. Just as significantly, HSV1716 increased survival rates among mice with various human cancers. The Phase I/II trial at Sheffield Experimental Cancer Medicine Centre is the next stage in development of HSV1716 as a viable mesothelioma treatment. The goal of…

  • | |

    New Mesothelioma Drug Kills Cancer Stem Cells

    Citing “significant enthusiasm within the mesothelioma community”, the manufacturers of a promising new mesothelioma drug say they have begun a major test of the drug in patients. Massachusetts-based Verastem, Inc. focuses on drugs that fight cancer by attacking the stem cells that give rise to them. Earlier this summer, the FDA granted orphan drug status to their stem cell inhibitor, defactinib, for the treatment of mesothelioma. The designation, which is reserved for drugs that fight the rarest of diseases, helps pave the way for testing and faster approval, depending on the results of clinical trials. “Development of a drug that preferentially kills cancer stem cells is a promising approach, as many standard-of-care treatments have been shown to either have no…